Biocatalystwatch
...KOEN

Regulatory Meetings & Hearings

Upcoming meetings and hearings with regulatory agencies.

3 events · 3 companiesPublic 30-day window through Dec 21, 2026 (ET)

Scheduled catalysts

Next CatalystCompanyDrugPrice · 30DCurrent stage
NEONC TECHNOLOGIES HOLDINGS, INC.NTHI
DrugNEO212
Indication—three proposed parallel patient cohorts: brain metastases, IDH1-mutant astrocytoma and recurrent IDH1-wildtype glioblastoma
—
RegulatoryRegulatory meetingNov 23, 2026
US

meet with the FDA on November 23, 2026 for an End-of-Phase 1 Type B meeting

SEC filing
Program milestone
Price · 30D
$3.15+6.8%
30D · 11/20
Biodexa Pharmaceuticals PlcBDRX
DrugMTX240
Indication—
—
RegulatoryRegulatory meetingDec 10, 2026
US

A pre-IND meeting with the FDA is scheduled

Company source
Program milestone
Price · 30D
$1.88-43.4%
30D · 11/20
VP
Vanda Pharmaceuticals Inc.VNDA
IndicationJet lag disorder
Target · MT1 × MT2
RegulatoryRegulatory meetingDec 14-18, 2026
US

a five-day hearing before the Administrative Law Judge from December 14, 2026 to December 18, 2026

SEC filing
Highest reached · Phase 2
Price · 30D
$3.45-14.8%
30D · 11/20

Showing 3 of 3 available events